Clinical Trial Update: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) [Phase 3]

View source ↗

Summary

Results from the Phase 3 LAURA trial evaluating osimertinib after chemoradiation in stage III unresectable non-small cell lung cancer have been posted. The resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Cancer (Stage III) | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-03